Multiple System Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major multiple system atrophy markets reached a value of US$ 129.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 187.2 Million by 2034, exhibiting a growth rate (CAGR) of 3.41% during 2024-2034.
The multiple system atrophy market has been comprehensively analyzed in IMARC's new report titled "Multiple System Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Multiple system atrophy (MSA) is a rare and progressive neurodegenerative disorder that generally impacts the autonomic nervous system and the motor system. The symptoms of MSA primarily include a combination of indications such as parkinsonism (tremors, stiffness, and slow movements), loss of balance and coordination, difficulty speaking and swallowing, problems with bladder and bowel control, and changes in blood pressure regulation that cause fainting spells. Due to its resemblance to other neurological disorders and the lack of precise diagnostic testing, diagnosing MSA can be difficult. A conclusive diagnosis of MSA usually requires a combination of clinical, neurological, and imaging evaluations. A clinical evaluation includes a detailed medical history, physical examination, and an assessment of the patient's motor function, balance, speech, and cognition. A neurological assessment consists of tests, such as a spinal tap, electroencephalography, and electromyography. Numerous imaging studies, including MRI and PET scans, are utilized to help identify changes in the brain that are characteristic of MSA.
The rising prevalence of neurogenerative disorders along with the increasing unmet clinical need for treatment is primarily driving the global multiple system atrophy market. In addition to this, the introduction of specific diagnostic criteria, such as the MSA consensus criteria, which help to enhance the accuracy of MSA diagnosis and reduce the number of misdiagnoses, is also creating a positive outlook for the market. Besides this, the emerging popularity of non-pharmacological approaches, such as physiotherapy, occupational therapy, and speech therapy, to assist in managing the symptoms and improving the quality of life for people with MSA is also bolstering the global market. Furthermore, several technological advancements in the field of neuroscience, including the introduction of advanced imaging technologies and gene editing, are augmenting the development of novel diagnostic tools and treatments for MSA. This, in turn, is acting as a significant growth-inducing factor. Apart from this, extensive investments in research activities aimed at analyzing the potential of stem cell therapy for regenerating damaged neurons and improving disease symptoms are expected to drive the global multiple system atrophy market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the multiple system atrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for multiple system atrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple system atrophy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the multiple system atrophy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the multiple system atrophy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current multiple system atrophy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the multiple system atrophy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the multiple system atrophy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the multiple system atrophy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of multiple system atrophy across the seven major markets?
What is the number of prevalent cases (2018-2034) of multiple system atrophy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of multiple system atrophy by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of multiple system atrophy by type across the seven major markets?
How many patients are diagnosed (2018-2034) with multiple system atrophy across the seven major markets?
What is the size of the multiple system atrophy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of multiple system atrophy?
What will be the growth rate of patients across the seven major markets?
Multiple System Atrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for multiple system atrophy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the multiple system atrophy market?
What are the key regulatory events related to the multiple system atrophy market?
What is the structure of clinical trial landscape by status related to the multiple system atrophy market?
What is the structure of clinical trial landscape by phase related to the multiple system atrophy market?
What is the structure of clinical trial landscape by route of administration related to the multiple system atrophy market?
The multiple system atrophy market has been comprehensively analyzed in IMARC's new report titled "Multiple System Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Multiple system atrophy (MSA) is a rare and progressive neurodegenerative disorder that generally impacts the autonomic nervous system and the motor system. The symptoms of MSA primarily include a combination of indications such as parkinsonism (tremors, stiffness, and slow movements), loss of balance and coordination, difficulty speaking and swallowing, problems with bladder and bowel control, and changes in blood pressure regulation that cause fainting spells. Due to its resemblance to other neurological disorders and the lack of precise diagnostic testing, diagnosing MSA can be difficult. A conclusive diagnosis of MSA usually requires a combination of clinical, neurological, and imaging evaluations. A clinical evaluation includes a detailed medical history, physical examination, and an assessment of the patient's motor function, balance, speech, and cognition. A neurological assessment consists of tests, such as a spinal tap, electroencephalography, and electromyography. Numerous imaging studies, including MRI and PET scans, are utilized to help identify changes in the brain that are characteristic of MSA.
The rising prevalence of neurogenerative disorders along with the increasing unmet clinical need for treatment is primarily driving the global multiple system atrophy market. In addition to this, the introduction of specific diagnostic criteria, such as the MSA consensus criteria, which help to enhance the accuracy of MSA diagnosis and reduce the number of misdiagnoses, is also creating a positive outlook for the market. Besides this, the emerging popularity of non-pharmacological approaches, such as physiotherapy, occupational therapy, and speech therapy, to assist in managing the symptoms and improving the quality of life for people with MSA is also bolstering the global market. Furthermore, several technological advancements in the field of neuroscience, including the introduction of advanced imaging technologies and gene editing, are augmenting the development of novel diagnostic tools and treatments for MSA. This, in turn, is acting as a significant growth-inducing factor. Apart from this, extensive investments in research activities aimed at analyzing the potential of stem cell therapy for regenerating damaged neurons and improving disease symptoms are expected to drive the global multiple system atrophy market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the multiple system atrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for multiple system atrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple system atrophy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the multiple system atrophy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the multiple system atrophy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current multiple system atrophy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the multiple system atrophy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the multiple system atrophy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the multiple system atrophy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of multiple system atrophy across the seven major markets?
What is the number of prevalent cases (2018-2034) of multiple system atrophy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of multiple system atrophy by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of multiple system atrophy by type across the seven major markets?
How many patients are diagnosed (2018-2034) with multiple system atrophy across the seven major markets?
What is the size of the multiple system atrophy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of multiple system atrophy?
What will be the growth rate of patients across the seven major markets?
Multiple System Atrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for multiple system atrophy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the multiple system atrophy market?
What are the key regulatory events related to the multiple system atrophy market?
What is the structure of clinical trial landscape by status related to the multiple system atrophy market?
What is the structure of clinical trial landscape by phase related to the multiple system atrophy market?
What is the structure of clinical trial landscape by route of administration related to the multiple system atrophy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MULTIPLE SYSTEM ATROPHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MULTIPLE SYSTEM ATROPHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MULTIPLE SYSTEM ATROPHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 MULTIPLE SYSTEM ATROPHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MULTIPLE SYSTEM ATROPHY - UNMET NEEDS
10 MULTIPLE SYSTEM ATROPHY - KEY ENDPOINTS OF TREATMENT
11 MULTIPLE SYSTEM ATROPHY - MARKETED PRODUCTS
11.1 List of Multiple System Atrophy Marketed Drugs Across the Top 7 Markets
11.1.1 Northera (Droxidopa) - Sumitomo Pharma/Lundbeck
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MULTIPLE SYSTEM ATROPHY - PIPELINE DRUGS
12.1 List of Multiple System Atrophy Pipeline Drugs Across the Top 7 Markets
12.1.1 TAK-341 - Takeda
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Verdiperstat - Biohaven Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 LuAF82422 - Lundbeck A/S
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ATH 434 - Alterity therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 hOMSC300 - Cytora Ltd
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MULTIPLE SYSTEM ATROPHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MULTIPLE SYSTEM ATROPHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MULTIPLE SYSTEM ATROPHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Multiple System Atrophy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Multiple System Atrophy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Multiple System Atrophy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Multiple System Atrophy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Multiple System Atrophy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Multiple System Atrophy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Multiple System Atrophy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Multiple System Atrophy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Multiple System Atrophy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Multiple System Atrophy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Multiple System Atrophy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Multiple System Atrophy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Multiple System Atrophy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Multiple System Atrophy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Multiple System Atrophy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Multiple System Atrophy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Multiple System Atrophy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Multiple System Atrophy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Multiple System Atrophy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Multiple System Atrophy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Multiple System Atrophy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Multiple System Atrophy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Multiple System Atrophy - Access and Reimbursement Overview
16 MULTIPLE SYSTEM ATROPHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MULTIPLE SYSTEM ATROPHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MULTIPLE SYSTEM ATROPHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MULTIPLE SYSTEM ATROPHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MULTIPLE SYSTEM ATROPHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MULTIPLE SYSTEM ATROPHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 MULTIPLE SYSTEM ATROPHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MULTIPLE SYSTEM ATROPHY - UNMET NEEDS
10 MULTIPLE SYSTEM ATROPHY - KEY ENDPOINTS OF TREATMENT
11 MULTIPLE SYSTEM ATROPHY - MARKETED PRODUCTS
11.1 List of Multiple System Atrophy Marketed Drugs Across the Top 7 Markets
11.1.1 Northera (Droxidopa) - Sumitomo Pharma/Lundbeck
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 MULTIPLE SYSTEM ATROPHY - PIPELINE DRUGS
12.1 List of Multiple System Atrophy Pipeline Drugs Across the Top 7 Markets
12.1.1 TAK-341 - Takeda
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Verdiperstat - Biohaven Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 LuAF82422 - Lundbeck A/S
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ATH 434 - Alterity therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 hOMSC300 - Cytora Ltd
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MULTIPLE SYSTEM ATROPHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MULTIPLE SYSTEM ATROPHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MULTIPLE SYSTEM ATROPHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Multiple System Atrophy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Multiple System Atrophy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Multiple System Atrophy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Multiple System Atrophy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Multiple System Atrophy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Multiple System Atrophy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Multiple System Atrophy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Multiple System Atrophy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Multiple System Atrophy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Multiple System Atrophy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Multiple System Atrophy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Multiple System Atrophy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Multiple System Atrophy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Multiple System Atrophy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Multiple System Atrophy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Multiple System Atrophy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Multiple System Atrophy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Multiple System Atrophy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Multiple System Atrophy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Multiple System Atrophy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Multiple System Atrophy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Multiple System Atrophy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Multiple System Atrophy - Access and Reimbursement Overview
16 MULTIPLE SYSTEM ATROPHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MULTIPLE SYSTEM ATROPHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MULTIPLE SYSTEM ATROPHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
